Not Tagged
Not Tagged
['sclc', 'lcsm,(-blcsm)', 'nsclc']
rilvegostomig demonstrated promising early signs of tolerability and efficacy in advanced or metastatic pd-l1 positive nsclc following progression on at least 1 prior checkpoint inhibitor. #asco23 #asco2023 #lcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.